Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Down 4.3% Following Weak Earnings

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s stock price dropped 4.3% on Monday following a weaker than expected earnings announcement. The stock traded as low as $23.13 and last traded at $23.24. Approximately 58,981 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 269,650 shares. The stock had previously closed at $24.28.

The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same period in the prior year, the business posted ($1.18) EPS.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KMTS. Bank of America began coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued a “buy” rating and a $30.00 price objective for the company. The Goldman Sachs Group assumed coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a “neutral” rating and a $24.00 price target on the stock. Wolfe Research began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an “outperform” rating and a $29.00 price objective for the company. Piper Sandler initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They set an “overweight” rating and a $27.00 target price on the stock. Finally, Wells Fargo & Company assumed coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They issued an “overweight” rating and a $28.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Kestra Medical Technologies Trading Down 1.9 %

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.